Literature DB >> 36169691

Development and validation of a deep learning signature for predicting lymph node metastasis in lung adenocarcinoma: comparison with radiomics signature and clinical-semantic model.

Xiaoling Ma1, Liming Xia2, Jun Chen3, Weijia Wan4, Wen Zhou4.   

Abstract

OBJECTIVE: To develop and validate a deep learning (DL) signature for predicting lymph node (LN) metastasis in patients with lung adenocarcinoma.
METHODS: A total of 612 patients with pathologically-confirmed lung adenocarcinoma were retrospectively enrolled and were randomly divided into training cohort (n = 489) and internal validation cohort (n = 123). Besides, 108 patients were enrolled and constituted an independent test cohort (n = 108). Patients' clinical characteristics and CT semantic features were collected. The radiomics features were derived from contrast-enhanced CT images. The clinical-semantic model and radiomics signature were built to predict LN metastasis. Furthermore, Swin Transformer was adopted to develop a DL signature predictive of LN metastasis. Model performance was evaluated by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, calibration curve, and decision curve analysis. The comparisons of AUC were conducted by the DeLong test.
RESULTS: The proposed DL signature yielded an AUC of 0.948-0.961 across all three cohorts, significantly superior to both clinical-semantic model and radiomics signature (all p < 0.05). The calibration curves show that DL signature predicted probabilities fit well the actual observed probabilities of LN metastasis. DL signature gained a higher net benefit than both clinical-semantic model and radiomics signature. The incorporation of radiomics signature or clinical-semantic risk predictors failed to reveal an incremental value over the DL signature.
CONCLUSIONS: The proposed DL signature based on Swin Transformer achieved a promising performance in predicting LN metastasis and could confer important information in noninvasive mediastinal LN staging and individualized therapeutic options. KEY POINTS: • Accurate prediction for lymph node metastasis is crucial to formulate individualized therapeutic options for patients with lung adenocarcinoma. • The deep learning signature yielded an AUC of 0.948-0.961 across all three cohorts in predicting lymph node metastasis, superior to both radiomics signature and clinical-semantic model. • The incorporation of radiomics signature or clinical-semantic risk predictors into deep learning signature failed to reveal an incremental value over deep learning signature.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Computer tomography; Deep learning; Lung adenocarcinoma; Lymph node; Radiomics

Year:  2022        PMID: 36169691     DOI: 10.1007/s00330-022-09153-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  40 in total

Review 1.  Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer.

Authors:  Asha Kandathil; Fernando U Kay; Yasmeen M Butt; Jason W Wachsmann; Rathan M Subramaniam
Journal:  Radiographics       Date:  2018 Nov-Dec       Impact factor: 5.333

2.  Propensity-Matched Analysis Comparing Survival After Sublobar Resection and Lobectomy for cT1N0 Lung Adenocarcinoma.

Authors:  Xu-Heng Chiang; Hsao-Hsun Hsu; Min-Shu Hsieh; Chia-Hong Chang; Tung-Ming Tsai; Hsien-Chi Liao; Kuan-Chuan Tsou; Mong-Wei Lin; Jin-Shing Chen
Journal:  Ann Surg Oncol       Date:  2019-10-23       Impact factor: 5.344

3.  Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).

Authors:  Nasser K Altorki; Xiaofei Wang; Dennis Wigle; Lin Gu; Gail Darling; Ahmad S Ashrafi; Rodney Landrenau; Daniel Miller; Moishe Liberman; David R Jones; Robert Keenan; Massimo Conti; Gavin Wright; Linda J Veit; Suresh S Ramalingam; Mohamed Kamel; Harvey I Pass; John D Mitchell; Thomas Stinchcombe; Everett Vokes; Leslie J Kohman
Journal:  Lancet Respir Med       Date:  2018-11-12       Impact factor: 30.700

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 5.  Current trends and emerging diagnostic techniques for lung cancer.

Authors:  Bala Prabhakar; Pravin Shende; Steffi Augustine
Journal:  Biomed Pharmacother       Date:  2018-07-28       Impact factor: 6.529

6.  A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201).

Authors:  Kenji Suzuki; Teruaki Koike; Takashi Asakawa; Masahiko Kusumoto; Hisao Asamura; Kanji Nagai; Hirohito Tada; Tetsuya Mitsudomi; Masahiro Tsuboi; Taro Shibata; Haruhiko Fukuda; Harubumi Kato
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

7.  Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis.

Authors:  Kyoungjune Pak; Sohyun Park; Gi Jeong Cheon; Keon Wook Kang; In-Joo Kim; Dong Soo Lee; E Edmund Kim; June-Key Chung
Journal:  Ann Nucl Med       Date:  2015-02-06       Impact factor: 2.668

8.  Central Tumor Location at Chest CT Is an Adverse Prognostic Factor for Disease-Free Survival of Node-Negative Early-Stage Lung Adenocarcinomas.

Authors:  Hyewon Choi; Hyungjin Kim; Chang Min Park; Young Tae Kim; Jin Mo Goo
Journal:  Radiology       Date:  2021-02-23       Impact factor: 11.105

9.  Predicting pathological lymph node status in clinical stage IA peripheral lung adenocarcinoma.

Authors:  Keiju Aokage; Kenji Suzuki; Masashi Wakabayashi; Tomonori Mizutani; Aritoshi Hattori; Haruhiko Fukuda; Shun-Ichi Watanabe
Journal:  Eur J Cardiothorac Surg       Date:  2021-07-14       Impact factor: 4.191

10.  Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching's Study.

Authors:  Bo Zhang; Renwang Liu; Dian Ren; Xiongfei Li; Yanye Wang; Huandong Huo; Shuai Zhu; Jun Chen; Zuoqing Song; Song Xu
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.